BioCentury | Aug 4, 2017
Company News

CVS unveils changes to 2018 formulary

...drug Elelyso taliglucerase alfa and diabetes drug Jardiance empagliflozin from its 2018 Standard Control Formulary . Elelyso...
BioCentury | Aug 3, 2017
Politics & Policy

CVS unveils changes to 2018 formulary

...drug Elelyso taliglucerase alfa and diabetes drug Jardiance empagliflozin from its 2018 Standard Control Formulary . Elelyso...
BioCentury | Jul 28, 2017
Regulation

Ganging up in rare disease

...in 2016. In 2012 EMA rejected a marketing authorization for Protalix BioTherapeutics Inc. ’s Elelyso taliglucerase alfa...
BioCentury | May 20, 2017
Strategy

Henri: N of 1

...setbacks in addition to the entry of Vpriv velaglucerase alfa from Shire plc and Elelyso taliglucerase alfa...
BioCentury | Dec 16, 2016
Company News

Protalix sales and marketing update

...Protalix said the Brazilian Ministry of Health issued a letter requesting three shipments of alfataliglicerase to...
...end of 2017. The plant cell-expressed recombinant form of human glucocerebrosidase (GCase) is approved as Uplyso...
...patients ages four and older. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX), Carmiel, Israel Business: Endocrine/Metabolic Nora Weintraub Uplyso Protalix...
BioCentury | Nov 16, 2015
Company News

Protalix, Pfizer deal

...sharing portion of a 2009 deal granting the pharma rights to develop and commercialize Elelyso taliglucerase alfa...
...original deal, Pfizer and Protalix had shared revenues and expenses on a 60/40 basis worldwide. Elelyso...
BioCentury | Sep 15, 2014
Clinical News

Elelyso taliglucerase alfa regulatory update

...FDA approved an sNDA from Pfizer for Elelyso taliglucerase alfa as long-term enzyme replacement therapy for pediatric...
...disease. The plant cell-expressed recombinant form of human glucocerebrosidase (GCase) is already approved in adults. Elelyso...
...Carmiel, Israel Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Elelyso taliglucerase alfa ( Uplyso alfataliglicerase), (formerly prGCD...
BioCentury | Jun 30, 2014
Clinical News

Oral glucocerebrosidase: Phase IIa started

...a 2-day washout period between doses. An injectable formulation of PRX-112 is marketed as Elelyso taliglucerase alfa...
...Pfizer Inc. (NYSE:PFE, New York, N.Y.) has exclusive rights outside of Israel and Brazil to taliglucerase alfa...
BioCentury | Jun 9, 2014
Clinical News

Elelyso regulatory update

...Protalix said Health Canada approved Elelyso taliglucerase alfa for long-term enzyme replacement therapy in adults and pediatric...
...replacement therapy in adults and pediatric patients with Type 1 Gaucher's disease. The company said Elelyso...
...Carmiel, Israel Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Elelyso ( Uplyso ) taliglucerase alfa (formerly prGCD...
BioCentury | May 26, 2014
Clinical News

Elelyso regulatory update

...Protalix said Australia's Therapeutic Goods Administration ( TGA ) approved Elelyso taliglucerase alfa to treat Type 1...
...and pricing details to Pfizer, which has exclusive rights outside of Israel and Brazil to taliglucerase alfa...
...Carmiel, Israel Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Elelyso ( Uplyso ) taliglucerase alfa (formerly prGCD...
Items per page:
1 - 10 of 125